NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Chime Biologics

Chime Biologics

Private
WuhanHealthcare & Life Scienceshttps://chimebiologics.com/

Last Round

Series A

Extension

Mar 25, 2021

Total Funding Raised

$190M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Chime Biologics is a biotechnology company that provides comprehensive contract development and manufacturing organization (CDMO) services for biologics, supporting clients from early-stage development to commercial production.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Pharma Supply Chain

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

CDMObiopharmaceutical manufacturingcontract manufacturingcell line developmentGMP manufacturingbiologicsbiosimilarsfill and finishprocess developmentclinical manufacturingCMCbiotech outsourcingdrug development servicesmonoclonal antibodiesbioprocessing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Chime Biologics Comparables

Compare Chime Biologics with similar companies based on industry and business-model similarity.

Chime Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Canton Biologics
93%
Bioworkshops
89%
Zencore Biologics
88%

Chime Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionMar 25, 2021

Chime Biologics Investors

Notable investors and investment history

Chime Biologics investors
InvestorRounds
VMS GroupSeries A Extension
Fidelity InternationalSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Monthly visitors grew 105% MoM, reaching 1.7K.

  • Oct 20, 2025

    Developing anti-ccr9 antibody SRB5 with SunRock Biopharma.

Chime Biologics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Chime Biologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Chime Biologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWuhan
Employee Range30
Year Founded2013
Last FundingMar 25, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.